Interferon gamma human recombinant (IFN-G)

DRUG4 trials

Sponsors

SPP Pharmaclon Ltd.

Conditions

Acute Respiratory DiseaseAnogenital WartsCOVID-19 Respiratory InfectionChronic ProstatitisHuman Papillomavirus Infection

Phase 3

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts

CompletedNCT05156541

SPP Pharmaclon Ltd.Anogenital Warts, Human Papillomavirus Infection

Start: 2009-05-18End: 2010-07-15Updated: 2021-12-14

Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis

CompletedNCT05378646

SPP Pharmaclon Ltd.Chronic Prostatitis

Start: 2009-01-29End: 2010-02-28Updated: 2022-05-18

Unknown Phase

Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

CompletedNCT05054114

SPP Pharmaclon Ltd.Acute Respiratory Disease, COVID-19 Respiratory Infection

Start: 2020-12-21End: 2021-09-02Updated: 2024-08-09

Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19

CompletedNCT05386446

SPP Pharmaclon Ltd.COVID-19 Respiratory Infection

Start: 2020-04-23End: 2020-06-15Updated: 2022-05-23